Fixing the market failure in antibiotics production means
transforming pharma companies — or parts of them — into public goods producers, with public interest rather than profit driving R&D and marketing.
Similarly, innovation in collaborative, patient - centric drug development models that are being promoted by
pharma companies, regulators and patient groups, have the ability to
transform the industry and improve productivity significantly.